{"url_path":"/sec/cccc/8-k/2026-06-11/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-042365-index.html","accession_number":"0001628280-26-042365","cik":"0001662579","ticker":"CCCC","issuer_name":"C4 Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-042365-index.html","primary_entity_key":"0001662579","primary_entity_name":"C4 Therapeutics, Inc."},"word_count":158,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn June 11, 2026, the Company posted on its website a poster presentation with further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (“RRMM”), to be presented at the European Hematology Association 2026 Congress (“EHA 2026 Congress”). A copy of the poster presentation, which has been published to the “Events & Presentations” section of the Company’s website, is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nOn June 11, 2026, the Company also issued a Press Release reporting further analysis from the Phase 1 trial of cemsidomide in combination with dexamethasone for the treatment of RRMM to be presented at the EHA Congress. A copy of the Press Release is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference."}